Simple and multivariable linear regression with DAS28-AUC at 24 months as dependent variable and ACPA reactivities and treatment as covariates presented with significant results
| ACPA reactivities and treatment | Simple | Multivariable | ||||
| β value | P value | 95% CI | β value | P value | 95% CI | |
| Fil307-324 | 3.57 | 0.011 | 0.80 to 6.34 | −1.44 | 0.502 | −5.63 to 2.76 |
| Vim60-75 | 2.74 | 0.055 | −0.06 to 5.53 | 0.09 | 0.965 | −3.75 to 3.92 |
| Vim2-17 | 4.91 | 0.004* | 1.60 to 8.23 | 3.57 | 0.047 | 0.05 to 7.08 |
| Pept-5 | 2.84 | 0.043 | 0.09 to 5.59 | −0.32 | 0.875 | −4.34 to 3.70 |
| F4-R-CIT | 2.88 | 0.041 | 0.12 to 5.64 | −0.37 | 0.852 | −4.28 to 3.53 |
| cDMARDs†, months | −0.21 | 0.810 | −0.25 to 0.20 | – | – | – |
| bDMARDs‡, months | 0.72 | 0.000 | 0.44 to 1.00 | 0.66 | 0.000 | 0.38 to 0.95 |
| Corticosteroids§, months | 0.42 | 0.000 | 0.29 to 0.56 | 0.39 | 0.000 | 0.25 to 0.53 |
Filaggrin (Fil307-324), vimentin (Vim) 2-17, Vim60-75, mutated proteins (Pept-5) and collagen type II (F4-R-CIT). Adjusted for sex and age.
*Indicates p value remaining significant after correction for number of tests performed.
† Conventional DMARDs: methotrexate, sulfasalazine, chloroquine, myocrisine, azathioprine, ciclosporin and leflunomide.
‡Biologal DMARDs: adalimumab, etanercept and infliximab.
§Corticosteroids ≤7.5 mg daily of prednisolone.
ACPA, anticitrullinated peptide antibody; bDMARDs, biologicals disease-modifying antirheumatic drugs; cDMARDs, conventional disease-modifying antirheumatic drugs.